Properties (135)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
biotechnology company
|
| gptkbp:acquisition |
Acquired by a larger pharmaceutical company
|
| gptkbp:advertising |
focused on unmet medical needs
aims to address unmet medical needs. |
| gptkbp:benefits |
aims to improve quality of life
|
| gptkbp:budget |
publishes detailed financial reports.
|
| gptkbp:businessModel |
biopharmaceutical development
focused on innovation and collaboration. |
| gptkbp:CEO |
gptkb:Dr._R._Scott_Greer
|
| gptkbp:challenges |
navigates competitive landscape.
|
| gptkbp:clinicalTrials |
gptkb:idiopathic_pulmonary_fibrosis
biopharmaceutical company Phase 1, Phase 2, Phase 3 published in journals innovative methodologies Phase 2 trials promising results focused on innovative therapies achieved on schedule utilizes advanced technologies Phase 1, Phase 2. across multiple sites aimed at chronic diseases aims for rapid advancement. employs adaptive trial designs. involves multiple stages of testing. promising results in early trials. published in scientific conferences. utilizes innovative approaches. Pliant Therapeutics is conducting clinical trials for therapies. various_sites_across_the_United_States. |
| gptkbp:collaborations |
gptkb:University_of_California,_San_Francisco
with academic institutions with research institutions with hospitals and clinics with biotech firms with leading hospitals with leading universities. with biotech firms. with leading research institutions. |
| gptkbp:community_engagement |
active in patient advocacy
involved in local health initiatives. |
| gptkbp:community_outreach |
supporting local health initiatives
engages with patient advocacy groups. |
| gptkbp:community_service |
measured in trials
integrated into development process developed for patients. engaged with organizations focused on safety and efficacy. |
| gptkbp:competitors |
conducted regularly
conducted for strategic planning analyzes industry trends. |
| gptkbp:culturalHeritage |
collaborative environment
|
| gptkbp:drugInterdiction |
advanced delivery systems
navigated effectively prioritized in development |
| gptkbp:employeeCount |
growing team of scientists and professionals.
|
| gptkbp:employees |
approximately 50
|
| gptkbp:enrollment |
diverse demographics
focuses on diverse demographics. increasing in trials |
| gptkbp:feedback |
monitored closely
|
| gptkbp:financialPerformance |
growing revenue
|
| gptkbp:financials |
provides updates on progress.
|
| gptkbp:focus |
fibrotic diseases
|
| gptkbp:founded |
2015
|
| gptkbp:founder |
gptkb:Dr._R._Scott_Greer
|
| gptkbp:funding |
secured from investors
receives grants for research initiatives. secured significant venture capital funding. |
| gptkbp:future_plans |
expand pipeline
expand pipeline and research. to advance therapies to market. |
| gptkbp:headquarters |
gptkb:South_San_Francisco,_California
|
| gptkbp:healthcare |
prioritizes in all trials.
|
| https://www.w3.org/2000/01/rdf-schema#label |
Pliant Therapeutics
|
| gptkbp:investmentFocus |
2020
$100 million various venture capital firms Venture capital firms transparent communication maintains active communication with investors. |
| gptkbp:leads |
PLI-101
|
| gptkbp:market |
pulmonary and fibrotic diseases
treatment of chronic diseases. |
| gptkbp:mission |
improve patient outcomes
to develop therapies for fibrotic diseases. |
| gptkbp:partnerships |
gptkb:Bristol-Myers_Squibb
with academic institutions with healthcare organizations. collaborates with various pharmaceutical companies fosters strategic alliances. with global pharmaceutical companies. |
| gptkbp:patentCitation |
patents filed
holds multiple patents for drug candidates. |
| gptkbp:platforms |
integrated drug discovery platform.
proprietary drug development |
| gptkbp:publications |
peer-reviewed journals
contributes to peer-reviewed journals. |
| gptkbp:reach |
international partnerships
|
| gptkbp:recruitment |
actively seeks participants.
|
| gptkbp:regulatoryCompliance |
gptkb:FDA
timely and efficient stringent standards FDA_approved_trials. adheres_to_FDA_guidelines. |
| gptkbp:research |
conducts extensive preclinical studies.
|
| gptkbp:research_areas |
gptkb:pulmonary_fibrosis
autoimmune diseases in various stages of development driven by research cardiac fibrosis develops multiple candidates for treatment. drives research and development. small molecule therapeutics targeting TGF-beta signaling targeting TGF-beta signaling. liver_fibrosis |
| gptkbp:research_focus |
small molecule therapies
|
| gptkbp:researchAndDevelopment |
ongoing
|
| gptkbp:social_responsibility |
committed to ethical practices.
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
PLRX
|
| gptkbp:supplyChain |
PLIant-1
|
| gptkbp:supportRole |
composed of industry experts
composed of industry experts. |
| gptkbp:sustainability_initiatives |
environmentally responsible practices
|
| gptkbp:targetMarket |
strategizes for successful product launch.
|
| gptkbp:team |
experienced in drug development
experienced in drug development. |
| gptkbp:tributaryOf |
multiple drug candidates
multiple drug candidates in development |
| gptkbp:vision |
transforming the treatment of fibrotic diseases
|
| gptkbp:website |
www.pliantrx.com
www.plianttherapeutics.com |